CPRX: Catalyst Pharmaceuticals, Inc. Stock

by  •  • Comments Off on CPRX: Catalyst Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,765.95
Enterprise Value ($M) 2,323.62
Book Value ($M) 660.94
Book Value / Share 5.54
Price / Book 4.18
NCAV ($M) 427.93
NCAV / Share 3.59
Price / NCAV 6.46

Profitability (mra)
Return on Invested Capital (ROIC) 0.21
Return on Assets (ROA) 0.30
Return on Equity (ROE) 0.37

Liquidity (mrq)
Quick Ratio 4.92
Current Ratio 5.11

Balance Sheet (mrq) ($M)
Current Assets 539.00
Assets 772.01
Liabilities 111.07
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Flynn James E 5.22 -29.92
11-08 13G/A BlackRock, Inc. 16.00 0.00
10-17 13G/A State Street Corp 4.80 -16.24
02-13 13G/A Vanguard Group Inc 6.68 5.20

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q 4r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPOR
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-31 182,158 749,604 24.30
2025-01-30 139,432 754,310 18.48
2025-01-29 188,283 934,878 20.14
2025-01-28 94,015 489,676 19.20
2025-01-27 70,290 532,825 13.19

(click for more detail)

Similar Companies
COEP – Coeptis Therapeutics Holdings, Inc. CORT – Corcept Therapeutics Incorporated
COYA – Coya Therapeutics, Inc. CRBP – Corbus Pharmaceuticals Holdings, Inc.
CRDF – Cardiff Oncology, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Catalyst Pharmaceuticals